Risk factors for pneumonitis in solid tumors treated with anti-programmed death-1 therapy: A case-control study.

被引：1
|
作者：
Cui, Pengfei
Liu, Zhefeng
Wang, Guoqiang
Ma, Junxun
Qian, Yuanyu
Zhang, Fan
Han, Chun
Long, Yaping
Li, Ye
Zheng, Xuan
Sun, Danyang
Zhang, Jing
Cai, Shangli
Jiao, Shun Chang
Hu, Yi
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol 1, Beijing, Peoples R China
[2] Gen Hosp PLA, Beijing, Peoples R China
[3] 3D Med Inc, Dept Med, Shanghai, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Buttous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review
    de Lorenzi, C.
    Andre, R.
    Vuilleumier, A.
    Kaya, G.
    Abosaleh, M.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (03): : 221 - 227
  • [22] Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors
    Sobecki-Rausch, Janelle
    Barroilhet, Lisa
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
  • [23] Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
    Okamoto, Masahide
    Okamoto, Mitsuhiro
    Gotoh, Koro
    Masaki, Takayuki
    Ozeki, Yoshinori
    Ando, Hisae
    Anai, Manabu
    Sato, Asami
    Yoshida, Yuichi
    Ueda, So
    Kakuma, Tetsuya
    Shibata, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (06) : 915 - 918
  • [24] Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-Programmed Cell Death Ligand 1 Therapy: A Case Series
    Yun, Jenny Sung Won
    Chan, Louis
    Goh, Michelle
    McCormack, Chris
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 18 - 18
  • [25] Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience
    Al jarroudi, Ouissam
    Chaabouni, Hamed
    Ulusakarya, Ayhan
    Almohamad, Wathek
    Gumus, Yusuf
    Goldschmidt, Emma
    Afqir, Said
    Morere, Jean-francois
    CLINICAL CASE REPORTS, 2021, 9 (04): : 2162 - 2167
  • [26] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Lee, Yong Jun
    Lee, Jii Bum
    Ha, Sang-Jun
    Kim, Hye Ryun
    MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
  • [27] Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
    Liu, Gang
    Zhou, Wenxuan
    Li, Xiaoli
    Guo, Lijie
    He, Tingting
    Zhao, Juan
    Gong, Liansheng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [28] Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
    Lee, Ye Jin
    Kim, Hak Tae
    Won, Chong Hyun
    Chang, Sung Eun
    Lee, Mi Woo
    Choi, Jee Ho
    Lee, Woo Jin
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (26)
  • [29] Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Piejko, Karolina
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Zemelka, Tomasz
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    MELANOMA RESEARCH, 2021, 31 (01) : 49 - 57
  • [30] Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy
    Zhou, Li
    Shao, Lizhi
    Gao, Shunyu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Yan, Xieqiao
    Wang, Xuan
    Bai, Xue
    Li, Siming
    Guo, Jun
    Si, Lu
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 112 - 121
12345